Candriam S.C.A. Sells 179,618 Shares of Guardant Health, Inc. $GH

Candriam S.C.A. lessened its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 51.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 172,874 shares of the company’s stock after selling 179,618 shares during the period. Candriam S.C.A.’s holdings in Guardant Health were worth $7,364,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in GH. NewEdge Advisors LLC boosted its stake in shares of Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after buying an additional 230 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Guardant Health in the fourth quarter valued at approximately $61,000. GF Fund Management CO. LTD. bought a new stake in shares of Guardant Health in the fourth quarter valued at approximately $79,000. TD Waterhouse Canada Inc. boosted its stake in shares of Guardant Health by 126.2% in the fourth quarter. TD Waterhouse Canada Inc. now owns 2,929 shares of the company’s stock valued at $89,000 after buying an additional 1,634 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Guardant Health in the first quarter valued at approximately $97,000. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Evercore ISI upgraded Guardant Health to a “strong-buy” rating in a research note on Monday, July 14th. Canaccord Genuity Group boosted their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. TD Securities boosted their price objective on shares of Guardant Health from $56.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. Stifel Nicolaus boosted their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. Finally, Mizuho boosted their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Friday, June 13th. One analyst has rated the stock with a Strong Buy rating and sixteen have given a Buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $57.50.

Insider Activity at Guardant Health

In related news, Director Musa Tariq sold 3,213 shares of the stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $49.47, for a total value of $158,947.11. Following the completion of the sale, the director directly owned 7,190 shares in the company, valued at $355,689.30. This represents a 30.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Myrtle S. Potter sold 2,626 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $49.70, for a total value of $130,512.20. Following the completion of the sale, the director owned 18,180 shares of the company’s stock, valued at $903,546. The trade was a 12.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,542 shares of company stock valued at $11,852,491. 6.10% of the stock is owned by company insiders.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $61.28 on Friday. The company has a fifty day moving average of $50.02 and a 200-day moving average of $45.87. The company has a market capitalization of $7.64 billion, a PE ratio of -18.29 and a beta of 1.43. Guardant Health, Inc. has a 52-week low of $20.14 and a 52-week high of $62.08.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.08. The company had revenue of $232.09 million for the quarter, compared to analyst estimates of $211.19 million. The firm’s quarterly revenue was up 31.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.